What is Epsilogen?
Epsilogen is at the forefront of developing advanced antibody therapeutics, specializing in pan-isotype antibody treatments for various cancers. The company's unique strategy involves leveraging immunoglobulin IgE, IgA, and IgG-based therapies. Its lead candidate, MOv18 IgE, represents a first-in-class therapeutic IgE antibody currently in clinical trials, targeting folate receptors in patients with platinum-resistant ovarian cancer. Epsilogen's research aims to enhance anti-cancer efficacy by precisely matching antibody isotypes to specific cancer types and exploring synergistic combinations to optimize immune responses. This innovative platform positions Epsilogen as a key player in the evolving landscape of oncology drug development.
How much funding has Epsilogen raised?
Epsilogen has raised a total of $67.8M across 3 funding rounds:
Series A
$6.3M
Other Financing Round
$3.9M
Series B
$57.6M
Series A (2017): $6.3M with participation from Epidarex Capital, Alsa Holdings, and UCL Technology Fund
Other Financing Round (2020): $3.9M led by Epidarex Capital, UCL Technology Fund, and Alsa Holdings
Series B (2024): $57.6M supported by British Patient Capital, 3B Future Health Fund, ALSA Ventures, Caribou Property Management, Novartis Venture Fund, Epidarex Capital, and Schroders Capital
Key Investors in Epsilogen
British Patient Capital
British Patient Capital, part of the British Business Bank, is a government-owned economic bank that supports UK businesses by providing access to finance, including equity investment, to foster growth and innovation.
Novartis Venture Fund
The Novartis Venture Fund is a venture capital arm that invests in innovative life science companies, particularly in biotechnology and biopharmaceutical therapeutics, aiming to address unmet patient needs and drive clinical advancements.
Epidarex Capital
Epidarex Capital is a transatlantic venture capital firm dedicated to building breakthrough life science companies, leveraging deep scientific networks to support founders and co-investors in developing precision medicines.
What's next for Epsilogen?
With the recent major strategic investment, Epsilogen is poised to accelerate the clinical development of its promising pipeline, particularly MOv18 IgE. The substantial capital infusion will likely support further clinical trials, expand research into other cancer indications, and bolster the company's operational capabilities. This funding round, characterized as enterprise-level, suggests a significant scaling phase for Epsilogen, enabling it to advance its therapies towards commercialization and solidify its position in the competitive biopharmaceutical market. The company's focus on novel antibody isotypes and combination therapies indicates a forward-looking strategy to address unmet needs in cancer treatment.
See full Epsilogen company page
